Biopharmaceutical Manufacturing & Biosimilar Expansion: Sandoz Unveils “Bio100” Long-Term Roadmap Targeting 100+ Biosimilars by 2040 – Commits $300M to New Biomanufacturing Facility in Slovenia to Capture $300B Patent Expiration Wave

Key Development

On September 8, 2026, Swiss generic and biosimilar manufacturer Sandoz Group AG officially presented its long-term commercial transformation strategy, designated as the “Bio100” plan, during its institutional Capital Markets Day. Under this framework, Sandoz aims to scale its commercial biosimilar portfolio to more than 100 approved assets by 2040, expanding from its current foundation of 13 marketed biosimilars.

Key strategic metrics, financial forecasts, and manufacturing capital deployment:

• Loss of Exclusivity (LOE) value coverage: Expanding addressable originator patent-loss value coverage from approximately 50% today to roughly 80% starting from 2035 onward.

• Net sales and profitability targets: Sandoz projects a doubling of net sales from 2025 through the mid-2030s, building upon the $11.1 billion net sales (5% constant-currency growth) reported for the preceding fiscal year. For the 2025–2030 midterm horizon, management targets compound annual net sales growth at a mid-to-high single-digit rate at constant exchange rates, alongside a target core EBITDA margin exceeding 30% by 2035.

• Addressable originator market opportunity: Targeting approximately $300 billion in originator LOE sales between 2026 and 2040. The aggregate off-patent market opportunity across generics and biosimilars is projected at $260 billion through 2030, increasing to $350 billion (2031–2035) and $370 billion during the late 2030s.

• Capturing the “Biosimilar Void”: Targeting an addressable segment comprising more than 60 branded biologics expected to lose exclusivity through 2032 that currently have no publicly disclosed biosimilar programs in active development.

• $300 Million drug substance facility investment in Slovenia: Sandoz announced a $300 million capital project to construct a new biomanufacturing facility in Ljubljana, Slovenia. The investment will add 8,000 liters of disposable fed-batch bioprocessing capacity to support clinical batches and commercial supply for low-to-medium volume drug substances, scheduled to be operational in 2029. The facility is co-located with Sandoz’s biosimilar development center, augmenting an integrated European manufacturing network (France, Germany, UK, Slovenia) backed by approximately $1 billion in regional capital allocations.

Why It Matters

• Preparing for an industry patent cliff: The late 2020s and early 2030s represent a concentrated period of patent expirations across major therapeutic monoclonal antibodies and fusion proteins. Establishing a 100-asset portfolio framework enables Sandoz to secure early regulatory submissions and tender positions across global markets.

• Therapeutic focus across oncology and immunology: The Bio100 program concentrates internal R&D capital on high-value immunology and oncology biologics, prioritizing complex monoclonal antibodies and in-house cell-line development over lower-margin small-molecule products.

• Reshoring supply chain security within Europe: Deploying $300 million in Ljubljana reinforces an integrated European bioproduction footprint. This domestic infrastructure insulates Sandoz from global supply chain disruptions and geopolitical trade tensions while meeting EMA and US FDA regulatory standards.

Healthcare Insight Analysis

From the perspective of Healthcare Insight, Sandoz’s Bio100 strategy announced on September 8, 2026, illustrates Large-Scale Industrialization of Biosimilars and Unaddressed Niche Market Capture.

The strategic execution highlights three primary biopharmaceutical dynamics:

1. Systematic targeting of the “Biosimilar Void”: Rather than competing solely in crowded segments targeting primary blockbuster biologic assets (such as initial adalimumab or ustekinumab entries), Sandoz is deploying resources toward more than 60 off-patent biologics that lack active pipeline competition. Achieving first-to-market status in these uncrowded categories provides more durable pricing power.

2. Flexible bioprocessing via single-use modular systems: Utilizing 8,000 liters of single-use fed-batch bioreactor technology in Slovenia enables modular multiproduct manufacturing. Compared to traditional fixed stainless-steel facilities, single-use systems reduce cross-contamination risks and lower changeover turnaround times across diverse product lines.

3. Sandoz’s enterprise re-rating post-Novartis separation: Following its corporate spin-off from Novartis, Sandoz is repositioning its core equity profile. Targeting doubled revenues and EBITDA margins above 30% reflects a corporate pivot from high-volume small-molecule commodity generics to specialized, higher-margin biosimilar production.

Market Implications

1. Intensifying global biosimilar competition: Sandoz’s 100-drug roadmap raises the competitive baseline for global biosimilar competitors, including Samsung Bioepis, Celltrion, Amgen, Fresenius Kabi, and Biocon, across hospital tenders and pharmacy benefit manager (PBM) formularies.

2. Sustained cross-border licensing transactions: While prioritizing in-house engineering, Sandoz will continue selective external in-licensing agreements to accelerate pipeline timelines, illustrated by its $322 million licensing agreement with Shanghai Henlius Biotech.

3. Long-term healthcare budget optimization: The introduction of over 100 biosimilar alternatives provides institutional health systems and commercial payers with additional options to contain biological therapy expenditures.

Strategic Summary Matrix: Sandoz Bio100 Long-Term Roadmap (2026–2040)

Source: https://www.fiercepharma.com/pharma/sandoz-aims-biosimilar-dominance-under-new-strategy-300m-facility-sweetener-slovenia